Adding zabilugene almadenorepvec to standard gemcitabine/nab-paclitaxel extends survival and response in newly diagnosed metastatic pancreatic cancer, with manageable safety signals.
|Videos|October 28, 2016
How Mutation Status Affects Individualization of Treatment in mCRC
Author(s)Maria Ignez Braghiroli, MD
Maria Ignez Braghiroli, MD, medical oncologist, Instituto do Câncer do Estado de São Paulo, discusses how mutation status effects individualization of treatment in metastatic colorectal cancer (mCRC).
Advertisement
Advertisement
Related to this article
Proton therapy did not improve overall survival vs photon therapy in advanced hepatocellular carcinoma in the phase 3 NRG-GI003 trial.
Benjamin Herzberg, MD, discusses KRAS-mutant non–small cell lung cancer, upfront biomarker testing, and the emerging RAS inhibitor toolkit on Targeted Talks.
Broad oncology bundles falter; experts push smaller surgery/radiation episodes, better navigation, and AI analytics to improve value-based care.
In an interview, Peter Voorhees, MD, discusses his presentation of the CERVINO trial data from the International Myeloma Society meeting.
The oral FGFR2 inhibitor lirafugratinib is now FDA approved for the second-line treatment of cholangiocarcinoma harboring FGFR2 alterations.
New analysis tracks life-years gained from blood cancer therapies, revealing breakthrough inflection points, stubborn AML gaps, and inequities in access.
New 177Lu-dotatate radioligand therapy expands options for SSTR+ GEP-NETs, backed by NETTER-1 efficacy and key safety guidance.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Plinabulin Receives FDA Fast Track Designation in Post-ICI NSCLC
2
Denosumab Biosimilar Approved For Existing Oncology Indications
3
FDA Oncology Recap: Approvals, Designations, and Decisions in September 2026
4
Tile-Based Radiation Improves Local Control in Resected Brain Metastases
5